Susquehanna International Group’s ArriVent BioPharma AVBP Stock Holding History

Susquehanna International Group’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$713K	Sell	30,898 -211,930	-87%	-$4.79M	﹤0.01%	8773
2025 Q4	$4.89M	Buy	+242,828	New	+$5.05M	﹤0.01%	4055
2025 Q3	–	Sell	-29,611	Closed	-$582K	–	14106
2025 Q2	$645K	Sell	29,611 -7,180	-20%	-$149K	﹤0.01%	8579
2025 Q1	$680K	Buy	36,791 +18,955	+106%	+$464K	﹤0.01%	8214
2024 Q4	$475K	Buy	+17,836	New	+$512K	﹤0.01%	8785

Other funds holding AVBP

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Susquehanna International Group's AVBP Position: Q1 2026 in Review

Susquehanna International Group reduced its ArriVent BioPharma (AVBP) stake by 87% in Q1 2026, selling an estimated $4.79M and leaving 30,898 shares worth $713K. The position accounts for ﹤0.01% of the portfolio, ranked #8773.

Susquehanna International Group first reported a position in AVBP in Q4 2024 and has held it in 5 quarters since. The position peaked at $4.89M in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

Susquehanna International Group held 30,898 shares of ArriVent BioPharma worth $713K as of Q1 2026.
Susquehanna International Group sold 211,930 ArriVent BioPharma shares in Q1 2026, an estimated $4.79M.
ArriVent BioPharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8773 holding.
Susquehanna International Group first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 5 quarters since.
Susquehanna International Group's ArriVent BioPharma position peaked at $4.89M in Q4 2025.
139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.